Описание
Ход выполнения
Заболевания
Дата начала КИ
28.05.2018
Дата окончания КИ
21.02.2022
Организация, проводящая КИ
Merck KGaA, Darmstadt, Germany
Фаза КИ
IV
Цель КИ
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
Количество пациентов
270
Источник